Thelansis

 Breast cancer cells lacking abnormal levels of HER2 proteins are classified as HER2-negative. This subgroup represents the largest and most diverse category, encompassing both hormone receptor (HR)-positive tumors. For HR-positive and HER2-negative metastatic disease, current guidelines recommend prioritizing endocrine therapy over chemotherapy as the initial treatment option. However, the management of HR-positive, HER2-negative patients primarily aims at control rather than cure, with overall 5-year survival rates falling between 30% and 45%. The age-adjusted rate of HR-negative/HER2-negative (HR-/HER2-) and HR-positive/HER2-negative (HR+/HER2-) breast cancer cases is estimated to be 13.2 and 87.2 per 100,000 women, respectively. ·        In the United States in 2023, approximately 20,380 individuals, comprising 11,410 males and boys and 8,970 females and girls, are expected to receive a diagnosis of AML across all age groups.   Thelansis’s “HER2-Negative Breast Cancer Market

 Breast cancer cells that don’t have abnormal levels of HER2 proteins are to be considered HER2-negative. In the United States, HER2-negative cases accounted for 78% of the newly diagnosed breast cancer; in ~5% to 8% of cases, the HER2 status was unknown. HER2-negative breast cancer represents the largest and most heterogeneous group because it includes both hr-positive tumors. In the case of hr-positive her2-negative metastatic disease, guidelines suggest that endocrine therapy, rather than chemotherapy, should be offered as standard first-line treatment. The treatment of hr-positive her2-negative patients is primarily non-curative, with overall 5-year survival rates ranging between 30% to 45%. Thelansis’s “HER2-Negative Breast Cancer Market Outlook, Epidemiology , Competitive Landscape , and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape,

  Breast cancer cells that don’t have abnormal levels of HER2 proteins are to be considered HER2-negative. In the United States, HER2-negative cases accounted for 78% of the newly diagnosed breast cancer and in ~5% to 8% of cases, the HER2 status was unknown. HER2-negative breast cancer represents the largest and most heterogeneous group because it includes both hr-positive tumors. In the case of hr-positive her2-negative metastatic disease, guidelines suggest that endocrine therapy, rather than chemotherapy, should be offered as standard first-line treatment. The treatment of hr-positive her2-negative patients is primarily non-curative with overall 5-year survival rates range between 30% to 45%.   The competitive landscape of HER2-negative Breast Cancer includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review and Accelerated Approval are being tracked and supplemented with analyst commentary. KOLs insights of HER2-negati